DBV Technologies S.A. logo
DBV Technologies S.A. DBVT
$ 18.28 7.47%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

DBV Technologies S.A. Income Statement 2011-2026 | DBVT

Annual Income Statement DBV Technologies S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

630 M 81.8 M 108 M 87.9 M 152 M 569 M 387 M 1.16 B 1.7 B 1.12 B 781 M - - -

Shares

97 M 95.1 M 77.4 M 54.9 M 57.8 M 57.8 M 57.8 M 49.5 M 48.9 M 43 M 32.2 M - - -

Historical Prices

6.5 0.86 1.39 1.6 2.62 10.7 6.42 24.6 35.1 36.3 27.1 - - -

Net Income

-114 M -72.7 M -96.3 M -97.8 M -160 M -154 M -166 M -148 M -115 M -44.7 M -24 M -19.3 M -13 M -7.24 M

Revenue

4.15 M 15.7 M 4.84 M 5.71 M - - - - - 202 K 211 K 182 K 174 K 126 K

Gross Profit

- - - - - - - - - 74 K 74.5 K 79.4 K 91.4 K 61 K

Operating Income

-117 M -76.4 M -96.6 M -98.6 M -159 M -171 M - - - - - - - -

EBITDA

-114 M -72.9 M -93.9 M -94.2 M -154 M -150 M -164 M -145 M -116 M -45.5 M -24.1 M -19.6 M -13.2 M -7.09 M

Operating Expenses

121 M 92.2 M 101 M 104 M 135 M 152 M 166 M 145 M 116 M 45.6 M 39 M 20 M 13.6 M 7.32 M

General and Administrative Expenses

28.7 M 29.5 M 24.3 M 30.5 M 40.1 M 56.4 M 52.2 M 42.4 M 39.8 M 16.9 M 8.12 M 6.31 M 4.62 M 2.39 M

All numbers in USD currency

Quarterly Income Statement DBV Technologies S.A.

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

134 M 103 M 96.2 M 96.2 M 96.2 M 96.1 M 94.3 M 94 M - 93.9 M 66 M 54.9 M - 54.9 M 54.9 M 54.9 M - 54.8 M 54.9 M 51.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-41.9 M -27.1 M -30.4 M -33.1 M -27.3 M -16.7 M -24.2 M -20.6 M - -17.3 M -23 M -16.7 M - -24 M -30.7 M -29.4 M - -31 M -48.2 M -40.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

1.46 M 753 K 1.07 M 1.16 M 1.41 M 2.37 M 2.29 M 2.19 M - 2.07 M 1.53 M 2.55 M - 1.32 M -1.49 M 2.94 M - 4.16 M 3.61 M 4.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-41.1 M -26.6 M -30.3 M -33.8 M -28.6 M -18.3 M -25.1 M -21.2 M - -18 M -23.8 M -16.8 M - -24.4 M -31.1 M -29.6 M - -29.8 M -47.7 M -41.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - -18 M -23.8 M -16.8 M - -24.4 M -31.1 M -29.6 M - -29.8 M -47.7 M -41.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

42.6 M 27.4 M 31.4 M 35 M 30 M 20.6 M 27.4 M 23.4 M - 20.1 M 25.4 M 19.3 M - 25.7 M 29.6 M 32.6 M - 33.9 M 51.3 M 45.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

8.46 M 5.63 M 7.22 M 8.64 M 7.8 M 6.18 M 9.23 M 6.89 M - 4.84 M 5.7 M 6.63 M - 8.3 M 8.27 M 9.68 M - 6.86 M 8.86 M 11.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company DBV Technologies S.A. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 1.65 7.91 % $ 92.9 M chinaChina
AstraZeneca PLC AstraZeneca PLC
AZN
$ 93.52 -1.2 % $ 96.9 B britainBritain
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.52 -16.3 % $ 388 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.59 1.99 % $ 8.64 B australiaAustralia
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Biogen Biogen
BIIB
$ 184.48 -1.67 % $ 26.9 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 102.17 2.32 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.25 1.67 % $ 9.25 B israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 207.49 2.22 % $ 5 B danmarkDanmark
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.84 0.46 % $ 714 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 37.35 -0.4 % $ 3.86 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.18 2.02 % $ 2.75 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.59 -6.54 % $ 1.65 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.22 -4.2 % $ 116 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.43 6.09 % $ 1.43 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.66 2.28 % $ 1.53 B britainBritain
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 66.05 2.3 % $ 8.83 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 55.11 3.49 % $ 4.45 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.14 -1.06 % $ 110 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.17 2.47 % $ 4.65 B schweizSchweiz
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 632.29 0.09 % $ 47.9 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 0.81 1.96 % $ 10.7 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.7 2.27 % $ 17 M usaUSA